Gilead Sciences, Inc. logo GILD - Gilead Sciences, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 35
HOLD 21
SELL 1
STRONG
SELL
0
| PRICE TARGET: $135.08 DETAILS
HIGH: $150.00
LOW: $105.00
MEDIAN: $135.00
CONSENSUS: $135.08
UPSIDE: 8.14%

About Gilead Sciences, Inc. (https://www.gilead.com)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Key Executives

NAME TITLE DOB SALARY
Daniel O'Day Chairman & Chief Executive Officer 1965 $7,137,565 USD
Johanna Mercier Chief Commercial Officer 1970 $3,169,442 USD
Deborah H. Telman Executive Vice President of Corporate Affairs, General Counsel & Corporate Secretary 1965 $3,107,954 USD
Andrew D. Dickinson Chief Financial Officer 1970 $2,729,705 USD
Bernard Fine VP of Oncology & Franchise Head of Early Development
Erin Burkhart SVP, Controller & Principal Accounting Officer 1979
Flavius Martin Executive Vice President of Research
Jacquie Ross Senior Vice President of Treasury and Investor Relations
Janet Dorling Senior Vice President of Intercontinental Region & Global Patient Solutions 1974
Jyoti K. Mehra Executive Vice President of Human Resources 1976
Linda Slanec Higgins Senior Vice President of Research, Innovation & Portfolio 1962